2,051
Views
14
CrossRef citations to date
0
Altmetric
Articles

Effects of huoxin formula on the arterial functions of patients with coronary heart disease

, , , , , , , , , & show all
Pages 13-20 | Received 11 Apr 2018, Accepted 06 Dec 2018, Published online: 14 Jun 2019
 

Abstract

Context: Huoxin formula is a Traditional Chinese Medicine for coronary heart disease (CHD) treatment.

Objective: To explore the therapeutic mechanism of the Huoxin formula on arterial functions in CHD patients.

Materials and methods: Fifty-eight CHD patients receiving cardiovascular drugs including β-receptor blocker, statins, and antiplatelet medications or others were randomized into intervention [additionally 13.5 g Huoxin formula granules dissolved in 150 mL warm water per time, twice a day (n = 30)] and control [only cardiovascular drugs (n = 28)] groups. Serum biomarkers (hs-CRP, IL-18, IL-17, TNF-α, MMP-9), and cardiovascular indicators of the common and internal carotid arteries (ICAs) were monitored before and after the treatments.

Results: After 3 months of treatment, the increases of intima-media thicknesses (IMT) of the left and right common carotid arteries (CCAs) as well as of the left and right ICAs and the increases of the left and right cardio-ankle vascular index were all significantly (all p < 0.001) less in the intervention than in control group (all p < 0.001). Serum concentrations reductions of hs-CRP, IL-18, IL-17 and MMP9 (all p < 0.001) levels were higher in the intervention compared to the control group, which correlated with the changes of left ICA (hs-CRP: r = 0.581, p = 0.009; IL-18: r = 0.594, p = 0.007; IL-17: r = 0.575, p = 0.006).

Discussion and conclusion: Since the Huoxin formula improved arterial functions and reduced inflammatory factor activities in CHD patients, a large-scale clinical trial is warranted.

Acknowledgements

We thank Professor Shiyun Yan from the Shanghai University of Traditional Chinese Medicine for providing the Huoxin formula.

Disclosure statement

The authors report no conflicts of interest.

Additional information

Funding

This work was supported by Shanghai Municipal Health Commission Funder of China [grant number: 20134153; 2018LP037; ZY(2018-2020)-CCCX-1009].